Lívia Mendes Carvalho

Lívia Mendes Carvalho

Auto-generated profile, based on publicly available information

Lívia Mendes Carvalho

Laboratório de Imunopatologia, Núcleo de Pesquisas em Ciências Biológicas/NUPEB, Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, Brasil

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Molecular Immunology
Verified
Journal Article
Closed access
JOJoão A. Oliveira-Da-Silva
João A. Oliveira-Da-Silva
DLDaniela P. Lage
Daniela P. Lage
FRFernanda F. Ramos
Fernanda F. Ramos
AMAmanda S. Machado
Amanda S. Machado
GTGrasiele S.V. Tavares
Grasiele S.V. Tavares
ECEDUARDO COELHO
EDUARDO COELHO

2 November 2021 in Parasitology
Verified
Journal Article
Open access
PDF file
LCLívia Mendes Carvalho
Lívia Mendes Carvalho
MGMiriã Rodrigues Gusmão
Miriã Rodrigues Gusmão
ACAna Flávia Pereira Costa
Ana Flávia Pereira Costa
RBRory Brito
Rory Brito
RARodrigo Dian de Oliveira Aguiar-Soares
Rodrigo Dian de Oliveira Aguiar-Soares
BRBruno Mendes Roatt
Bruno Mendes Roatt
The control of human visceral leishmaniasis (VL) is hard since there are no vaccines available as well as the treatment is hampered by toxicity and resistant parasites. Furthermore, as human, and canine VL causes immunosuppression, the combination of drugs with immunostimulatory agents is interesting to upregulate the immunity, reducing side-effects, improving treatment approaches against disease. Herein, we assessed the immunochemotherapy using miltefosine along with a vaccine formulated by Leishmania braziliensis antigens + saponin + monophosphoryl lipid-A (LBSapMPL) in L. infantum-infected hamsters. Two months after infection, the animals received treatments, and after 15 days they were evaluated for the treatment effect. The potential anti-Leishmania effect of miltefosine + LBSapMPL-vaccine was revealed by a specific immune response activation reflecting in control of spleen parasitism using half the miltefosine treatment time. The treated animals also showed an increase of total and T-CD4 splenocytes producing IFN-γ and TNF-α and a decrease of interleukin-10 and anti-Leishmania circulating IgG. In addition, it was demonstrated that the control of spleen parasitism is related to the generation of a protective Th1 immune response. Hence, due to the combinatorial action of miltefosine with LBSapMPL-vaccine in immunostimulating and controlling parasitism, this immunochemotherapy protocol can be an important alternative option against canine and human VL.